Targeting tissue immune memory in chronic-remitting autoimmune kidney diseases: current concepts and future therapies

Clicks: 8
ID: 328023
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #126 of 153 articles by views in clinical kidney journal

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 153 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Immune-mediated kidney diseases have a substantial disease burden and frequent disease relapses significantly contribute to the high morbidity. Relapsing disease courses are associated with poor outcome and accelerated progression to end-stage renal disease. The pathomechanisms leading to relapse are diverse and only incompletely understood. Both adaptive and innate immune cells are implicated in the immune memory of these diseases. In addition to antigen-dependent mechanisms of T and B cells, persistent epigenetic and metabolic changes in adaptive and innate immune cells may sustain immunological memory and thereby provide a cellular and molecular basis for relapse. Treatment options, especially in frequently relapsing cases, are limited and memory immune cells often evade standard immunosuppressive therapies. As our understanding of immunological memory continues to improve, new treatment options emerge. Improved depletion of B cells, antigen-specific cell-based therapies and redirecting epigenetic alterations may target long-lasting immune memory. This could reduce relapse risk and improve long-term outcomes in patients with immune-mediated kidney diseases.
Reference Key
openalex_W7211905195 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Malte Hellmig, Christian F. Krebs
Journal clinical kidney journal
Year 2026
DOI
10.1093/ckj/sfag299
URL
https://doi.org/10.1093/ckj/sfag299
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.